Antag Therapeutics Raises $88M Series A Financing Led by Versant Ventures

Why It Matters

The data positions AT7687 as a promising, tolerable backbone for next‑generation obesity and cardiometabolic therapies, potentially reshaping combination treatment strategies. Investors and clinicians will watch the upcoming Phase 2a trial for signals of differentiated efficacy.

Key Takeaways

• Phase 1 showed no serious adverse events or GI safety signals
• Once‑weekly subcutaneous dosing achieved consistent target engagement
• AT7687 + cagrilintide cut weight 12.2% vs 7.8% alone
• Combination improved glucose disposal by 18.9% versus decline
• Series A raised €80 M (~$87 M) to fund Phase 2a

Pulse Analysis

Antag Therapeutics’ first‑in‑human study of AT7687 marks a notable advance in obesity drug development. By antagonizing the glucose‑dependent insulinotropic polypeptide receptor (GIPR), AT7687 tackles a genetically validated pathway linked to fat storage and insulin resistance. The Phase 1 trial’s clean safety profile—no severe events and no gastrointestinal tolerability issues—addresses a common hurdle for peptide‑based obesity agents, positioning AT7687 as a viable weekly injection for patients seeking flexible regimens.

Beyond monotherapy, Antag highlighted compelling preclinical synergy with cagrilintide, a dual amylin‑calcitonin receptor agonist. In obese, insulin‑resistant non‑human primates, the combination achieved a 12.2% body‑weight reduction and an 18.9% boost in glucose disappearance, far outpacing cagrilintide alone. Notably, energy intake remained comparable, suggesting the added weight loss stems from metabolic effects rather than appetite suppression alone. This mechanistic complementarity could enable clinicians to tailor multi‑agent protocols that maximize efficacy while preserving tolerability.

The upcoming Phase 2a trial, slated for mid‑2026, will be the first clinical test of AT7687’s combination potential. Backed by a €80 million (~$87 million) Series A round led by Versant Ventures, Antag has the capital to accelerate development and explore co‑formulation strategies. If Phase 2 outcomes mirror the early data, AT7687 could become a cornerstone of next‑generation obesity treatment, offering a personalized, once‑weekly option that integrates seamlessly with existing therapies such as GLP‑1 or amylin analogues. The industry will be watching closely for signals that GIPR antagonism can deliver meaningful metabolic benefits without the gastrointestinal side effects that have limited prior candidates.

Deal Summary

Antag Therapeutics announced a €80 million ($88 million) Series A financing round led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma, Pictet, Longview Ventures and the Export and Investment Fund of Denmark. The capital will support further development of AT7687, a first‑in‑class GIPR antagonist for obesity and cardiometabolic disease. The announcement was made on June 7, 2026.